[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Caris Science, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100645293","caris-chromoseq-data-collection-100645293",false,"NCT07680868","Caris Chromoseq Data Collection","An Observational Study to Describe the Performance of Caris Chromoseq as Compared to Conventional Cytogenetics, FISH, and NGS Testing Among Patients Receiving the Caris Chromoseq Assay for Hematologic Malignancies","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Stated willingness to comply with all study procedures and availability for the duration of the study and has signed consent form\n2. Subject must be 18 or older\n3. Subject be diagnosed with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN)\n4. Physician must order or plan to order Caris Chromoseq for their patient\n5. Physicians must order or have ordered conventional cytogenetics, FISH, and NGS testing for AML, MDS, or MPN within the same timeframe of Caris Chromoseq without intervening line of therapy.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Patient for whom Caris Chromoseq is not being ordered\n2. Patient is pregnant or lactating\n3. Patient is not able or willing to provide consent to data collection for this protocol","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","OBSERVATIONAL","The study will collect clinical data on patients who receive the Caris Chromoseq assay for an underlying hematologic malignancy. The assay provides risk stratification for patients with acute myeloid leukemia (AML) myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN). The hypothesis of the study is that Caris Chromoseq compares favorably to conventional cytogenetics, FISH, and NGS analysis in terms of risk stratification capabilities, ease of use, and turnaround time.",[24,25,26,27],"Acute Myeloid Leukemia (AML)","Myelodysplastic (MDS) \u002F Myeloproliferative (MPN) Diseases","Myelodysplatic Syndromes","Myeloproliferative Neoplasm",[29,30,31,32,33],"Chromoseq","Caris","AML","MDS","MPN","RECRUITING","2026-06-26",{"date":37,"type":38},"2026-07-02","ACTUAL",{"date":40,"type":20},"2026-07",{"date":42,"type":20},"2029-07",{"name":44,"class":45},"Caris Science, Inc.","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100170984","caris-biorepository-research-protocol-100170984","NCT01499394","Caris Biorepository Research Protocol","The Caris Biorepository Research Protocol","Inclusion Criteria:\n\n* 18 years of age or older\n* Capacity to provide informed consent\n\nExclusion Criteria:\n\n* Due to the complexity of state and federal requirements governing the participation of prisoners in research, prisoners-patients will not be approached for participation in the Caris Biorepository.\n* Minor subjects will not be included in the Caris Biorepository, as it is possible biospecimens and data may be stored beyond the time limitations of assent and it may be impracticable to re-consent these subjects once they become adults.\n* Individuals who lack the capacity to give informed consent",true,{"count":56,"type":20},100000,"The Biorepository for Caris Life Sciences is designed for the purpose of making quality biospecimens and associated clinical data available for research studies related to advancing precision medicine and improving care for patients.\n\nThe Caris Biorepository is a repository of prospectively collected biological specimens and associated clinical and demographic data gathered from multiple sources to be stored, used and shared for research. Caris Life Sciences will maintain the data and specimens and will control access to and use of the information and specimens by multiple individuals for multiple purposes which may evolve over time.",[59,60,61],"Cancer","Early Detection of Cancer","Minimal Residual Disease",[63,64,65,66,67],"Caris Biorepository","MCED","Early Detection","MRD","Pan-Cancer","2026-01-19",{"date":70,"type":38},"2026-01-21",{"date":72,"type":4},"2010-11",{"date":74,"type":20},"2035-11",{"name":44,"class":45},38,""]